A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients
Not Applicable
Completed
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- Registration Number
- NCT00002054
- Lead Sponsor
- Fisons
- Brief Summary
To evaluate the safety, tolerability, and description of time to Pneumocystis carinii pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who have had one episode of AIDS-associated PCP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which aerosol pentamidine prevents Pneumocystis carinii pneumonia in HIV-positive patients?
How does the efficacy of 60 mg versus 120 mg aerosol pentamidine compare to standard PCP prophylaxis regimens in AIDS patients?
Which biomarkers correlate with successful prophylaxis outcomes in patients receiving aerosol pentamidine for PCP prevention?
What are the long-term adverse event profiles of aerosol pentamidine at 60 mg and 120 mg doses in immunocompromised individuals?
How do aerosolized pentamidine formulations compare to other inhaled antifungal agents like dapsone or atovaquone in PCP prevention for HIV/AIDS patients?
Trial Locations
- Locations (1)
Fisons Corp
🇺🇸Rochester, New York, United States
Fisons Corp🇺🇸Rochester, New York, United States